文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

含SAC3结构域1对能量代谢重编程的干预促进肝细胞癌进展。

SAC3 domain containing 1 intervention in energy metabolism reprogramming assists in the progression of hepatocellular carcinoma.

作者信息

Lin Xue-Jing, Tang Er-Jiang, Sun Bin, Wang Ai-Li, Chen Ying, Chen Lei, Xue Yi-Yang, Li A-Jian, Liu Chun-Ying

机构信息

Center for Clinical Research and Translational Medicine, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, China.

National Center for Liver Cancer, Naval Medical University, Shanghai 201805, China.

出版信息

World J Gastrointest Oncol. 2025 Jul 15;17(7):107971. doi: 10.4251/wjgo.v17.i7.107971.


DOI:10.4251/wjgo.v17.i7.107971
PMID:40697225
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12278251/
Abstract

BACKGROUND: Metabolic dysregulation is considered a significant hallmark of hepatocellular carcinoma (HCC). SAC3 domain containing 1 (SAC3D1) functions in the cell cycle, and its expression is upregulated in various cancers. It is known that metabolic changes occur at different stages of the cell cycle to maintain the biosynthesis and replication of both normal and cancer cells. Based on the role of SAC3D1 in mitosis, we hypothesize that abnormal expression of SAC3D1 may affect cellular metabolism. However, it remains unclear whether SAC3D1 mediates the progression of HCC by regulating metabolic reprogramming. AIM: To comprehensively elucidate the impact and molecular mechanism of SAC3D1 on the progression of HCC by regulating the metabolic reprogramming. METHODS: The constructed SAC3D1 overexpression and knockdown HCC cell lines were used for detecting cell proliferation, migration capabilities, as well as glycolysis and adenosine triphosphate (ATP) production rate assays. They were also employed for examining molecular markers associated with cell migration and glycolysis. The transcriptome sequencing data of cells have revealed the pathways potentially influenced by SAC3D1.The tail vein metastasis model and xenograft tumor experiments were utilized to demonstrate SAC3D1's tumor-promoting effects . RESULTS: SAC3D1 expression was upregulated and associated with poor prognosis in HCC patients. SAC3D1 enhanced the proliferation and migration abilities and reduced the population dependence of HCC cells and . The upregulation of SAC3D1 enhanced cellular glycolysis and ATP production. The cell transcriptome sequencing data revealed that SAC3D1 activated Wnt signaling pathway. SAC3D1 did not modulate the transcription of , while might inhibit its degradation. Further investigations indicated that the increase of SAC3D1 leads to more β-Catenin accumulating in the nucleus, facilitating the expression of c-Myc, one of the upstream regulatory factors of glycolysis. The iCRT3, an antagonist of β-Catenin, could counteract the increase of c-Myc induced by SAC3D1, while also downregulating the expression of glycolysis-related proteins. CONCLUSION: This study found that SAC3D1 enhances HCC cell glycolysis and ATP production the β-Catenin/c-Myc signaling axis, thereby promoting the progression of HCC.

摘要

背景:代谢失调被认为是肝细胞癌(HCC)的一个重要标志。含SAC3结构域蛋白1(SAC3D1)在细胞周期中发挥作用,其在多种癌症中表达上调。已知在细胞周期的不同阶段会发生代谢变化,以维持正常细胞和癌细胞的生物合成及复制。基于SAC3D1在有丝分裂中的作用,我们推测SAC3D1的异常表达可能影响细胞代谢。然而,SAC3D1是否通过调节代谢重编程介导HCC的进展仍不清楚。 目的:通过调节代谢重编程全面阐明SAC3D1对HCC进展的影响及分子机制。 方法:使用构建的SAC3D1过表达和敲低的HCC细胞系检测细胞增殖、迁移能力以及糖酵解和三磷酸腺苷(ATP)产生率测定。它们还用于检测与细胞迁移和糖酵解相关的分子标志物。细胞转录组测序数据揭示了可能受SAC3D1影响的通路。利用尾静脉转移模型和异种移植肿瘤实验来证明SAC3D1的促肿瘤作用。 结果:SAC3D1在HCC患者中表达上调且与预后不良相关。SAC3D1增强了HCC细胞的增殖和迁移能力,并降低了细胞群体依赖性。SAC3D1的上调增强了细胞糖酵解和ATP产生。细胞转录组测序数据显示SAC3D1激活了Wnt信号通路。SAC3D1未调节[具体基因]的转录,而可能抑制其降解。进一步研究表明,SAC3D1的增加导致更多β-连环蛋白在细胞核中积累,促进了糖酵解上游调节因子之一c-Myc的表达。β-连环蛋白拮抗剂iCRT3可以抵消SAC3D1诱导的c-Myc增加,同时也下调糖酵解相关蛋白的表达。 结论:本研究发现SAC3D1通过β-连环蛋白/c-Myc信号轴增强HCC细胞糖酵解和ATP产生,从而促进HCC进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/aa9c68a54415/wjgo-17-7-107971-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/05afec539154/wjgo-17-7-107971-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/75f3709e63ad/wjgo-17-7-107971-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/a606673926e3/wjgo-17-7-107971-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/25bca0802171/wjgo-17-7-107971-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/7a11a2912c82/wjgo-17-7-107971-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/6d50362267b2/wjgo-17-7-107971-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/7d20b725972a/wjgo-17-7-107971-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/aa9c68a54415/wjgo-17-7-107971-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/05afec539154/wjgo-17-7-107971-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/75f3709e63ad/wjgo-17-7-107971-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/a606673926e3/wjgo-17-7-107971-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/25bca0802171/wjgo-17-7-107971-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/7a11a2912c82/wjgo-17-7-107971-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/6d50362267b2/wjgo-17-7-107971-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/7d20b725972a/wjgo-17-7-107971-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/12278251/aa9c68a54415/wjgo-17-7-107971-g008.jpg

相似文献

[1]
SAC3 domain containing 1 intervention in energy metabolism reprogramming assists in the progression of hepatocellular carcinoma.

World J Gastrointest Oncol. 2025-7-15

[2]
Integrated network pharmacology and experimental validation reveal EGFR/p53/Bcl-2-mediated anti-hepatocellular carcinoma effects of Zedoary Turmeric Oil.

J Ethnopharmacol. 2025-7-3

[3]
Aberrant expression of cuproptosis‑related gene LIPT1 is associated with metabolic dysregulation of fatty acid and prognosis in hepatocellular carcinoma.

J Cancer Res Clin Oncol. 2023-11

[4]
Nuclear factor IA-mediated transcriptional regulation of crystallin αB inhibits hepatocellular carcinoma progression.

Mol Clin Oncol. 2025-6-20

[5]
Hepatitis B virus core/capsid protein induces hepatocellular carcinoma progression via long non-coding RNA KCNQ1OT1/miR-335-5p/CDC7 axis.

Transl Cancer Res. 2025-6-30

[6]
SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming.

J Exp Clin Cancer Res. 2025-7-18

[7]
Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular Carcinoma.

J Hepatocell Carcinoma. 2025-7-10

[8]
Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma.

J Exp Clin Cancer Res. 2025-7-15

[9]
Integrin αVβ1-activated PYK2 promotes the progression of non-small-cell lung cancer via the STAT3-VGF axis.

Cell Commun Signal. 2024-6-6

[10]
mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma.

Theranostics. 2022

本文引用的文献

[1]
Regulated Cell Death in Lenvatinib Resistance of Hepatocellular Carcinoma: from Molecular Mechanisms to Therapeutic Strategies.

Int J Biol Sci. 2025-2-18

[2]
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy.

Liver Int. 2024-8

[3]
Single-cell RNA-seq reveals T cell exhaustion and immune response landscape in osteosarcoma.

Front Immunol. 2024

[4]
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2024

[5]
Precision treatment in advanced hepatocellular carcinoma.

Cancer Cell. 2024-2-12

[6]
Centrosome amplification-related signature correlated with immune microenvironment and treatment response predicts prognosis and improves diagnosis of hepatocellular carcinoma by integrating machine learning and single-cell analyses.

Hepatol Int. 2024-2

[7]
Immunotherapies for advanced hepatocellular carcinoma.

Front Pharmacol. 2023-3-21

[8]
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.

Cancer Metastasis Rev. 2023-9

[9]
SAC3D1 activates Wnt/β‑catenin signalling in hepatocellular carcinoma.

Mol Med Rep. 2022-10

[10]
Metabolic oscillations during cell-cycle progression.

Trends Endocrinol Metab. 2022-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索